New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials
Journal of the European Academy of Dermatology and Venereology · 2025-08 · 39 (8) · 1410-1420
DOI: 10.1111/jdv.20234 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 05.08.2024. Verfasst von Anna Passera und 13 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG.
Abstract (Originalsprache)
Background
Defining hidradenitis suppurativa (HS) subtypes was previously limited by small sample sizes and poor interrater reliability; no study has investigated subtype treatment responses. The objective of this analysis was to characterize HS clusters in adult patients with moderate to severe HS and evaluate secukinumab treatment responses between clusters.
Methods
Clusters were identified via an unsupervised machine learning clustering analysis using baseline data from the randomized, placebo‐controlled SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) phase 3 trials. To assess treatment responses, patients received secukinumab every 2 (SECQ2W) or 4 weeks (SECQ4W) or placebo, for 16 weeks, after which, placebo patients randomly switched to SECQ2W/SECQ4W, and SECQ2W/SECQ4W patients maintained their original treatment, until week 52. Baseline outcomes included patient characteristics, disease characteristics and severity, HS‐associated comorbidities and previous treatment exposures. Treatment response was assessed via the HS clinical response (HiSCR), abscess and inflammatory nodule (AN) count, flares and NRS30 (skin pain).
Results
Based on baseline data, three clusters were identified from 1084 patients (Cluster 1: 54.1%, Cluster 2: 17.8%, Cluster 3: 28.1%). Cluster 1 was predominantly female (65.4%) and was characterized by milder HS. Cluster 2 had more patients from the Asia Pacific, Middle East and Africa region (58.5%) and was characterized by moderate HS. Cluster 3 had the highest rates of previous exposure to biologics (45.9%) and prior HS‐related surgeries (47.5%) and was characterized by severe HS. SECQ2W and SECQ4W demonstrated efficacy versus placebo in all clusters at week 16; SECQ2W and SECQ4W efficacy was maintained to week 52. SECQ2W treatment showed a trend for greater efficacy versus SECQ4W in Cluster 3 through week 52.
Conclusions
Three HS clusters were identified. Secukinumab demonstrated benefit over placebo in all clusters. However, patients with more severe disease may take longer to respond and more frequent secukinumab dosing may be required for these patients. Trial Registration SUNSHINE (NCT03713619) and SUNRISE (NCT03713632).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Gene Therapies, Bannockburn, Illinois, USA.
- Department of Dermatology, Howard University College of Medicine, Washington, D.C., USA.
- University of Copenhagen, Copenhagen, Denmark.
- University of Alabama at Birmingham, Birmingham, Alabama, USA.
- University of Southern California, Los Angeles, California, USA.
ORCID-Profile: Marc Vandemeulebroecke, Martina L Porter
Förderung
- Novartis Pharma AG
Zitieren
APA
Passera, A., Muscianisi, E., Demanse, D., Okoye, G. A., Jemec, G. B. E., Mayo, T., Hsiao, J., Shi, V. Y., Byrd, A. S., Wei, X., Uhlmann, L., Vandemeulebroecke, M., Ravichandran, S., & Porter, M. L. (2025). New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials. Journal of the European Academy of Dermatology and Venereology, 39(8), 1410-1420. https://doi.org/10.1111/jdv.20234
Vancouver
Passera A, Muscianisi E, Demanse D, Okoye GA, Jemec GBE, Mayo T, et al. New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials. Journal of the European Academy of Dermatology and Venereology. 2025;39(8):1410-1420. doi:10.1111/jdv.20234
BibTeX
@article{Passera2025,
author = {Passera, Anna and Muscianisi, Elisa and Demanse, David and Okoye, Ginette A and Jemec, Gregor B E and Mayo, Tiffany and Hsiao, Jennifer and Shi, Vivian Y and Byrd, Angel S and Wei, Xiaoling and Uhlmann, Lorenz and Vandemeulebroecke, Marc and Ravichandran, Shoba and Porter, Martina L},
title = {New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {8},
pages = {1410--1420},
doi = {10.1111/jdv.20234}
}
EUVIMED